{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 28,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a funnel diagram to represent the clinical development strategy, emphasizing learning and de-risking.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/12",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.58,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Prioritize expected high-probability-of-success combination trials with immunogenic chemo and/or radiation in tumors with high unmet need. Multiple Phase 2 readouts within the next ~12-18 months",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f630cd8-2c99-42f5-b5a7-48d8ef0c9b17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.38,
        "x": 0.58,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Multiple Trials, Learning and De-risking, Clinical Development Strategy",
      "attrs": null,
      "subkind": "funnel",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0921a82f-c882-42cd-93c9-759f30b2afe2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Data demonstrate single-agent anti-tumor activity; I-O naïve melanoma: 2 monotherapy CRs in ongoing trial. Data suggest efficacy in combination with anti-PD-1 in PD-1 blockade-refractory metastatic melanoma; Post-PD-1 melanoma: 15% ORR with DOR range 6 to 25 months. Data suggest efficacy in combination with tumoricidal agents; Neoadjuvant esophageal/GEJ: 41% pCRR (60% SCC, 35% adeno), 91% ORR; Advanced sarcoma: 20% ORR, 80% DCR (PR, SD). Duration of PR: range: 1.3 to 11 months. Duration of SD: 1.4 to 23.4 months. Reasonable safety profile with no additive or new toxicities when combined with other agents",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad55451a-d8da-46cb-9695-91927006a89c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "* Ongoing, enrolling studies; data continue to mature and are subject to change.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af572b21-da1c-42b8-93d5-78e5e794b5b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Highlights of Sotigalimab Phase 2 Clinical Development Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6493dbb1-f272-47fe-9d39-cfc898b3af15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "9bffe6d0-9557-43a3-b2f3-ec183760f950",
      "evidence": "The slide effectively uses clear and concise visuals, such as a funnel chart, to communicate complex information without unnecessary clutter.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "flywheel",
      "slug": null,
      "matchId": "d3334b4f-bb6d-45b0-8493-f200e24b8feb",
      "evidence": "The funnel diagram includes a circular arrow labeled 'Learning and De-risking' indicating a continuous improvement process.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 10,
      "beatId": "eabcce46-c7fe-4e05-b519-ae0aa88c80cb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The deck provides details on Sotigalimab's clinical development program and potential applications.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}